Top Markets
#1 MowCat MowCat +48.90%
#2 Bermuda Shorts Bermuda Shorts +35.34%
#3 aPriori aPriori +23.54%
#4 Derive Derive +19.62%
#5 Velvet Velvet +19.35%
#6 Biconomy Biconomy +19.15%
#7 Audiera Audiera +17.60%
#8 Quack AI Quack AI +17.21%
#9 Perle Perle +15.57%
#10 Block Street Block Street +11.88%
Coin of the day
MowCat MowCat
설정
언어
한국어
통화
USD
테마
Tricida, Inc. Tricida, Inc.

Tricida, Inc.

TCDA
주식 순위 #35026
Tricida, Inc. operates as a biopharmaceutical firm with a primary focus on the... Tricida, Inc. operates as a biopharmaceutical firm with a primary focus on the advancement and market introduction of veverimer (TRC101). This compound, an orally ingested, non-systemic polymer, has successfully concluded its Phase III clinical trials. Veverimer is designed to address metabolic acidosis in individuals suffering from chronic kidney disease by specifically targeting and eliminating excess acid within the gastrointestinal tract. The company was established in 2013 and is headquartered in South San Francisco, California.
주가
$0.108
마지막 동기화: 2023-01-23
시가총액
$4.56M
변동 (1일)
-10.00%
변동 (1년)
0.00%
국가
US
거래 Tricida, Inc. (TCDA)

카테고리

Healthcare
Tricida, Inc. (TCDA)의 EPS
2026 기준 EPS TTM: 0
Tricida, Inc.의 최신 재무 보고서와 주가에 따르면, 현재 EPS (TTM)는 0입니다. 2026년 말에는 회사의 EPS가 0였으며, 이는 2026년의 EPS 0와 동일입니다.
Tricida, Inc.의 EPS 기록 (2026 ~ 2026)
매년 말의 EPS
연도 EPS 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 EPS
회사 EPS EPS 차이 국가
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $17.32 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $27.74 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $13.70 -
BE